Monte Rosa Therapeutics, Inc. (GLUE) shareholders
Close on Nov 17, 2026Market cap $773.79MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Felix J. Baker Joint filing with Baker Bros. Advisors LP (9.99%), Baker Bros. Advisors (GP) LLC (9.99%) and 1 more | 8,876,346 | 9.99% | 13G (passive) amendment | Mar 31, 2026 |
| T. Rowe Price Associates, Inc. | 8,861,282 | 10.50% | 13G (passive) amendment | Jun 30, 2026 |
| Ali Behbahani Joint filing with New Enterprise Associates 17, L.P. (9.60%), NEA Partners 17, L.P. (9.60%) and 9 more | 7,797,030 | 9.70% | 13D (active) amendment | Mar 17, 2026 |
| Nea 17 Gp, LLC Joint filing with New Enterprise Associates 17, L.P. (7.90%), NEA Partners 17, L.P. (7.90%) and 3 more | 6,692,298 | 7.90% | 13D (active) amendment | Jul 1, 2026 |
| Adam Goulburn Joint filing with Zavain Dar (8.10%), Nan Li (8.10%) and 4 more | 6,513,765 | 8.10% | 13G (passive) amendment | Mar 31, 2026 |
| Dimension Capital I, L.P. Joint filing with Adam Goulburn (8.70%), Zavain Dar (8.70%) and 4 more | 5,663,265 | 8.70% | 13G (passive) amendment | Dec 31, 2025 |
| Lampert Mark N Joint filing with Bvf Partners L P/Il (6.30%), Bvf Inc/Il (6.30%) and 1 more | 5,085,886 | 6.30% | 13G (passive) amendment | Mar 31, 2026 |
| Chen Yu | 4,622,151 | 5.50% | 13G (passive) amendment | Mar 31, 2026 |
| Vestal Point Capital, LP Joint filing with Ryan Wilder (5.40%) | 4,600,000 | 5.40% | 13G (passive) | Jun 30, 2026 |
| Bvf Inc/Il Joint filing with Bvf Partners L P/Il (7.20%), Lampert Mark N (7.20%) and 1 more | 4,393,210 | 7.20% | 13G (passive) | Jan 24, 2025 |
| Baker Bros. Advisors LP Joint filing with Baker Bros. Advisors (GP) LLC (6.70%), Julian C. Baker (6.70%) and 1 more | 4,345,736 | 6.70% | 13G (passive) amendment | Dec 31, 2025 |
| BlackRock, Inc. | 3,840,165 | 6.30% | 13G (passive) | Dec 31, 2024 |
| Behzad Aghazadeh Joint filing with Avoro Capital Advisors LLC (6.10%) | 3,725,000 | 6.10% | 13G (passive) amendment | Jun 30, 2025 |
| Suvretta Capital Management, LLC Joint filing with Aaron Cowen (5.50%), Averill Master Fund, Ltd. (5.10%) | 3,360,000 | 5.50% | 13G (passive) | Apr 9, 2025 |
| Versant Ventures VI GP, L.P. Joint filing with Versant Venture Capital VI, L.P. (5.10%), Versant Ventures VI GP-GP, LLC (5.10%) | 3,334,669 | 5.10% | 13D (active) amendment | Nov 10, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of GLUE | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Price T Rowe Associates Inc /Md/ | 8,861,171 | 10.39% | $214.44M | +2,140,983 | 0.02% |
| NEA Management Company, LLC | 7,692,298 | 9.02% | $186.15M | – | 11.72% |
| BlackRock, Inc. | 6,843,087 | 8.02% | $165.60M | +1,205,403 | 0.00% |
| TCG Crossover Management, LLC | 4,622,151 | 5.42% | $111.86M | – | 2.69% |
| Vestal Point Capital, LP | 4,600,000 | 5.39% | $111.32M | +996,535 | 2.60% |
| Bvf Inc/Il | 4,460,886 | 5.23% | $107.95M | – | 2.76% |
| Baker Bros. Advisors LP | 4,345,736 | 5.09% | $105.17M | – | 0.53% |
| State Street Corp | 3,731,416 | 4.37% | $90.30M | +377,436 | 0.00% |
| Suvretta Capital Management, LLC | 3,549,539 | 4.16% | $85.90M | −677,270 | 1.57% |
| Vanguard Capital Management LLC | 3,412,927 | 4.00% | $82.59M | +312,682 | 0.00% |
| Versant Venture Management, LLC | 3,180,780 | 3.73% | $76.97M | – | 47.34% |
| Braidwell LP | 2,451,562 | 2.87% | $59.33M | −755,012 | 2.19% |
| Geode Capital Management, LLC | 1,864,113 | 2.19% | $45.12M | +323,301 | 0.00% |
| American Century Companies Inc | 1,622,846 | 1.90% | $39.27M | −1,186,801 | 0.02% |
| Marshall Wace, Llp | 1,593,600 | 1.87% | $38.57M | +160,448 | 0.03% |
| Aisling Capital Management LP | 1,555,664 | 1.82% | $37.65M | – | 7.98% |
| Nantahala Capital Management, LLC | 1,303,986 | 1.53% | $31.56M | +651,993 | 0.52% |
| Bellevue Group AG | 1,190,000 | 1.39% | $28.80M | −60,000 | 0.61% |
| Dimensional Fund Advisors LP | 1,177,488 | 1.38% | $28.49M | +136,116 | 0.01% |
| Mpm Bioimpact LLC | 1,161,081 | 1.36% | $28.10M | −15,847 | 1.71% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 193 | 93M | 100.0% | 28 / 82 | 59 / 23 | 15M | 8M |
| Q1 2026 | 191 | 87M | 100.0% | 52 / 84 | 41 / 20 | 29M | 4M |
| Q4 2025 | 161 | 64M | 75.6% | 49 / 53 | 40 / 16 | 14M | 10M |
| Q3 2025 | 129 | 60M | 70.4% | 27 / 36 | 40 / 14 | 6M | 8M |
| Q2 2025 | 116 | 63M | 73.5% | 28 / 49 | 18 / 17 | 8M | 5M |
| Q1 2025 | 105 | 60M | 69.8% | 23 / 22 | 44 / 21 | 5M | 7M |
| Q4 2024 | 104 | 61M | 71.5% | 34 / 35 | 18 / 11 | 16M | 4M |
| Q3 2024 | 81 | 50M | 58.3% | 14 / 40 | 12 / 7 | 7M | 1M |
| Q2 2024 | 75 | 46M | 53.8% | 14 / 33 | 13 / 6 | 7M | 1M |
| Q1 2024 | 68 | 40M | 46.9% | 10 / 21 | 21 / 13 | 1M | 1M |
| Q4 2023 | 71 | 40M | 47.1% | 13 / 16 | 24 / 13 | 2M | 4M |
| Q3 2023 | 71 | 42M | 49.3% | 7 / 31 | 17 / 4 | 3M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
199 funds held GLUE in Q2 2026, 47% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of GLUE | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,550,827 | 2.99% | $61.73M | 0.00% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 2,232,091 | 2.62% | $54.02M | 0.37% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,113,733 | 2.48% | $51.15M | 0.48% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,897,949 | 2.22% | $45.93M | 0.06% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1,823,210 | 2.14% | $44.12M | 0.37% | Jun 30, 2026 |
| Avantis U.S. Small Cap Value ETF | 1,688,329 | 1.98% | $33.28M | 0.12% | May 31, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 1,375,639 | 1.61% | $33.29M | 0.34% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 809,637 | 0.95% | $13.38M | 0.04% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 785,011 | 0.92% | $19.00M | 0.02% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 654,121 | 0.77% | $15.83M | 0.10% | Jun 30, 2026 |
| Vanguard Explorer Fund | 533,079 | 0.62% | $8.81M | 0.04% | Jul 31, 2026 |
| iShares Biotechnology ETF | 414,838 | 0.49% | $10.04M | 0.11% | Jun 30, 2026 |
| EA Bridgeway Omni Small-Cap Value ETF | 329,266 | 0.39% | $7.97M | 0.33% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 319,140 | 0.37% | $6.29M | 0.01% | May 31, 2026 |
| BlackRock Health Sciences Opportunities Portfolio | 318,162 | 0.37% | $6.27M | 0.11% | May 29, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Markus Warmuth | President & CEO, Director | 585,038 | 0.69% | Jul 17, 2026 |
| Matthew Bowen | Principal Accounting Officer | 25,891 | 0.03% | Oct 6, 2026 |
| Jennifer Champoux | Chief Operating Officer | 66,722 | 0.08% | Jul 16, 2026 |
| Sharon Townson | Chief Scientific Officer | 68,245 | 0.08% | Jul 7, 2026 |
| Filip Janku | Chief Medical Officer | 60,612 | 0.07% | Jul 1, 2026 |
| Philip Nickson | Chief Business & Legal Officer | 55,000 | 0.06% | Apr 10, 2026 |
| Edmund Dunn | Principal Accounting Officer | 22,554 | 0.03% | Mar 5, 2026 |
| Ali Behbahani | Director | 6,707,298 | 7.86% | Jul 6, 2026 |
| Anthony M. Manning | Director | 0 | – | Jun 30, 2026 |
| Christine Siu | Director | – | – | Jun 12, 2026 |
| Kimberly Blackwell | Director | – | – | Jun 12, 2026 |
| Jan Skvarka | Director | – | – | Jun 12, 2026 |
| Andrew N. Schiff | Director | – | – | Jun 12, 2026 |
| Eric A. Hughes | Director | – | – | Jun 12, 2026 |
| Chandra P. Leo | Director | 10,000 | 0.01% | Mar 25, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Matthew Bowen Principal Accounting Officer | Oct 5, 2026 | Sale | −13 | $10.56 | $137 | 25,891 |
| Markus Warmuth President & CEO, Director | Jul 16, 2026 | Sale | −9,500 | $23.18 | $220.21K | 585,038 |
| Jennifer Champoux Chief Operating Officer | Jul 15, 2026 | Option exercise | +4,351 | $3.98 | $17.32K | 66,722 |
| Jennifer Champoux Chief Operating Officer | Jul 15, 2026 | Sale(10b5-1 plan) | −4,351 | $23.38 | $101.73K | 62,371 |
| Sharon Townson Chief Scientific Officer | Jul 6, 2026 | Sale(10b5-1 plan) | −5,600 | $23.25 | $130.20K | 68,245 |
| Sharon Townson Chief Scientific Officer | Jul 6, 2026 | Option exercise | +6,000 | $6.14 | $36.84K | 73,845 |
| Sharon Townson Chief Scientific Officer | Jul 6, 2026 | Sale(10b5-1 plan) | −400 | $24.13 | $9.65K | 67,845 |
| Ali Behbahani Director | Jul 1, 2026 | Other | −1,000,000 | – | – | 6,692,298 |
| Ali Behbahani Director | Jul 1, 2026 | Other | +15,000 | – | – | 15,000 |
| Ali Behbahani Director | Jul 1, 2026 | Other | −15,000 | – | – | 0 |
| Filip Janku Chief Medical Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −5,407 | $24.50 | $132.47K | 60,612 |
| Filip Janku Chief Medical Officer | Jun 30, 2026 | Option exercise | +5,407 | $13.41 | $72.51K | 66,019 |
| Filip Janku Chief Medical Officer | Jun 29, 2026 | Sale(10b5-1 plan) | −6,000 | $22.95 | $137.70K | 59,992 |
| Filip Janku Chief Medical Officer | Jun 29, 2026 | Option exercise | +6,000 | $7.56 | $45.36K | 65,992 |
| Anthony M. Manning Director | Jun 29, 2026 | Sale | −10,000 | $23.11 | $231.10K | 0 |
| Anthony M. Manning Director | Jun 29, 2026 | Option exercise | +10,000 | $4.16 | $41.60K | 10,000 |
| Filip Janku Chief Medical Officer | Jun 24, 2026 | Option exercise | +30,000 | $7.56 | $226.80K | 89,992 |
| Filip Janku Chief Medical Officer | Jun 24, 2026 | Sale(10b5-1 plan) | −30,000 | $21.42 | $642.60K | 59,992 |
| Jennifer Champoux Chief Operating Officer | Jun 23, 2026 | Option exercise | +2,175 | $3.98 | $8.66K | 64,546 |
| Jennifer Champoux Chief Operating Officer | Jun 23, 2026 | Sale(10b5-1 plan) | −2,175 | $20.00 | $43.50K | 62,371 |
| Filip Janku Chief Medical Officer | Jun 23, 2026 | Option exercise | +6,000 | $7.56 | $45.36K | 71,837 |
| Filip Janku Chief Medical Officer | Jun 23, 2026 | Sale(10b5-1 plan) | −11,845 | $20.22 | $239.51K | 59,992 |
| Sharon Townson Chief Scientific Officer | Jun 23, 2026 | Sale(10b5-1 plan) | −3,000 | $20.00 | $60.00K | 67,845 |
| Sharon Townson Chief Scientific Officer | Jun 23, 2026 | Option exercise | +3,000 | $6.14 | $18.42K | 70,845 |
| Sharon Townson Chief Scientific Officer | Jun 17, 2026 | Sale(10b5-1 plan) | −3,000 | $19.00 | $57.00K | 67,845 |
| Sharon Townson Chief Scientific Officer | Jun 17, 2026 | Option exercise | +3,000 | $6.14 | $18.42K | 70,845 |
| Jennifer Champoux Chief Operating Officer | Jun 17, 2026 | Sale(10b5-1 plan) | −2,176 | $19.00 | $41.34K | 62,371 |
| Jennifer Champoux Chief Operating Officer | Jun 17, 2026 | Option exercise | +2,176 | $3.98 | $8.66K | 64,547 |
| Markus Warmuth President & CEO, Director | Jun 1, 2026 | Sale(10b5-1 plan) | −468 | $19.73 | $9.23K | 594,538 |
| Markus Warmuth President & CEO, Director | Jun 1, 2026 | Sale(10b5-1 plan) | −4,998 | $19.41 | $97.01K | 595,006 |
| Sharon Townson Chief Scientific Officer | May 29, 2026 | Sale(10b5-1 plan) | −6,000 | $19.87 | $119.22K | 67,845 |
| Sharon Townson Chief Scientific Officer | May 29, 2026 | Option exercise | +6,000 | $6.14 | $36.84K | 73,845 |
| Jennifer Champoux Chief Operating Officer | May 27, 2026 | Option exercise | +2,175 | $3.98 | $8.66K | 64,546 |
| Jennifer Champoux Chief Operating Officer | May 27, 2026 | Sale(10b5-1 plan) | −2,175 | $20.00 | $43.50K | 62,371 |
| Jennifer Champoux Chief Operating Officer | May 22, 2026 | Option exercise | +2,176 | $3.98 | $8.66K | 64,547 |
| Jennifer Champoux Chief Operating Officer | May 22, 2026 | Sale(10b5-1 plan) | −2,176 | $19.00 | $41.34K | 62,371 |
| Anthony M. Manning Director | May 21, 2026 | Sale | −10,000 | $18.01 | $180.10K | 0 |
| Anthony M. Manning Director | May 21, 2026 | Option exercise | +10,000 | $4.16 | $41.60K | 10,000 |
| Markus Warmuth President & CEO, Director | May 1, 2026 | Sale(10b5-1 plan) | −5,467 | $18.92 | $103.44K | 600,004 |
| Markus Warmuth President & CEO, Director | Apr 14, 2026 | Sale | −8,000 | $17.64 | $141.12K | 605,471 |
| Philip Nickson Chief Business & Legal Officer | Apr 9, 2026 | Sale | −5,845 | $17.69 | $103.40K | 55,000 |
| Matthew Bowen Principal Accounting Officer | Apr 6, 2026 | Award | +4,300 | – | – | 25,904 |
| Edmund Dunn Principal Accounting Officer | Mar 4, 2026 | Sale | −139 | $17.96 | $2.50K | 22,554 |
| Markus Warmuth President & CEO, Director | Mar 2, 2026 | Sale(10b5-1 plan) | −5,466 | $17.92 | $97.95K | 613,471 |
| Edmund Dunn Principal Accounting Officer | Mar 2, 2026 | Option exercise | +536 | $13.41 | $7.19K | 23,229 |
| Edmund Dunn Principal Accounting Officer | Mar 2, 2026 | Sale | −536 | $17.50 | $9.38K | 22,693 |
| Edmund Dunn Principal Accounting Officer | Feb 27, 2026 | Sale | −25,164 | $18.10 | $455.47K | 22,693 |
| Edmund Dunn Principal Accounting Officer | Feb 27, 2026 | Option exercise | +25,164 | $13.41 | $337.45K | 47,857 |
| Filip Janku Chief Medical Officer | Feb 23, 2026 | Sale | −9,189 | $19.50 | $179.19K | 65,837 |
| Markus Warmuth President & CEO, Director | Jan 7, 2026 | Sale(10b5-1 plan) | −3,707 | $23.24 | $86.15K | 620,696 |
| Markus Warmuth President & CEO, Director | Jan 7, 2026 | Sale(10b5-1 plan) | −1,450 | $23.88 | $34.63K | 619,246 |
| Markus Warmuth President & CEO, Director | Jan 7, 2026 | Sale(10b5-1 plan) | −309 | $24.57 | $7.59K | 618,937 |
| Edmund Dunn Principal Accounting Officer | Jan 5, 2026 | Sale | −1,039 | $15.17 | $15.76K | 22,693 |
| Filip Janku Chief Medical Officer | Jan 5, 2026 | Sale | −3,155 | $15.17 | $47.86K | 75,026 |
| Markus Warmuth President & CEO, Director | Jan 5, 2026 | Sale | −10,135 | $15.17 | $153.75K | 624,403 |
| Sharon Townson Chief Scientific Officer | Jan 5, 2026 | Sale | −3,155 | $15.17 | $47.86K | 67,845 |
| Philip Nickson Chief Business & Legal Officer | Jan 5, 2026 | Sale | −3,155 | $15.17 | $47.86K | 60,845 |
| Jennifer Champoux Chief Operating Officer | Jan 5, 2026 | Sale | −2,629 | $15.17 | $39.88K | 62,371 |
| Filip Janku Chief Medical Officer | Jan 2, 2026 | Award | +31,000 | – | – | 78,181 |
| Markus Warmuth President & CEO, Director | Jan 2, 2026 | Award | +90,000 | – | – | 634,538 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Monte Rosa Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 54,787 shares on Sep 17, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Markus Warmuth Officer | Jul 16, 2026 | 9,500 | $220.22K | Jul 16, 2026 | Restricted Stock |
| Jennifer Champoux Officer | Jul 15, 2026 | 4,351 | $101.73K | Jul 15, 2026 | Exercise of stock options |
| Filip Janku Officer | Jun 30, 2026 | 5,407 | $129.23K | Jun 30, 2026 | Exercise of Stock Options |
| Anthony M. Manning Director | Jun 29, 2026 | 10,000 | $231.10K | Jun 29, 2026 | Stock Option Exercise |
| Filip Janku Officer | Jun 29, 2026 | 6,000 | $133.74K | Jun 29, 2026 | Exercise of Stock Options |
| Filip Janku Officer | Jun 24, 2026 | 30,000 | $621.30K | Jun 24, 2026 | Exercise of Stock Options |
| Filip Janku Officer | Jun 23, 2026 | 11,845 | $221.15K | Jun 23, 2026 | Exercise of Stock Options |
| Jennifer Champoux Officer | Jun 23, 2026 | 2,175 | $40.04K | Jun 23, 2026 | Exercise of stock options |
| Edmund Dunn Officer | Jun 23, 2026 | 16,665 | $344.99K | Jun 23, 2026 | Stock Option Exercise |
| Jennifer Champoux Officer | Jun 17, 2026 | 2,176 | $39.00K | Jun 17, 2026 | Exercise of stock options |
| Markus Warmuth Officer | Jun 2, 2026 | 5,467 | $103.45K | May 1, 2026 | Stock Award |
| Markus Warmuth Officer | Jun 1, 2026 | 5,466 | $106.25K | Jun 1, 2026 | Stock Award |
| Sharon Townson Officer | May 29, 2026 | 24,000 | $465.36K | May 29, 2026 | Exercise of Stock Options |
| Jennifer Champoux Officer | May 27, 2026 | 2,175 | $42.04K | May 27, 2026 | Exercise of stock options |
| Jennifer Champoux Officer | May 22, 2026 | 2,176 | $40.73K | May 22, 2026 | Exercise of stock options |
See a number that looks wrong?